Citadel Advisors
KNTE

Citadel Advisors’s Kinnate Biopharma Inc. Common Stock KNTE Stock Holding History

Citadel Advisors’s Portfolio KNTE Stock Details KNTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,300
Closed -$3.46K – 15861
2024
Q1 		$3.46K Sell
1,300
-2,100
-62% -$5.2K ﹤0.01% 13903
2023
Q4 		$8.06K Buy
3,400
+900
+36% +$1.59K ﹤0.01% 13251
2023
Q3 		$3.5K Sell
2,500
-2,300
-48% -$5.52K ﹤0.01% 13576
2023
Q2 		$14.5K Sell
4,800
-1,400
-23% -$5.4K ﹤0.01% 12998
2023
Q1 		$38.8K Buy
6,200
+6,000
+3,000% +$36.6K ﹤0.01% 12464
2022
Q4 		$1.22K Sell
200
-21,600
-99% -$176K ﹤0.01% 14509
2022
Q3 		$261K Sell
21,800
-300
-1% -$3.93K ﹤0.01% 9874
2022
Q2 		$279K Sell
22,100
-3,000
-12% -$27.9K ﹤0.01% 9961
2022
Q1 		$283K Buy
+25,100
New +$276K ﹤0.01% 10731

Citadel Advisors's KNTE Position: Q2 2024 in Review

Citadel Advisors sold out of Kinnate Biopharma Inc. Common Stock (KNTE) in Q2 2024, closing a stake of 214,664 shares — an estimated $571K sold.

Citadel Advisors first reported a position in KNTE in Q4 2020 and held it in 14 quarters. The position peaked at $52.3M in Q4 2020. 0 funds tracked by Wall St. Rank hold KNTE as of Q2 2024.

  • Citadel Advisors reported no remaining Kinnate Biopharma Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Citadel Advisors sold 214,664 Kinnate Biopharma Inc. Common Stock shares in Q2 2024, an estimated $571K.
  • Citadel Advisors first reported a position in Kinnate Biopharma Inc. Common Stock in Q4 2020 and held it in 14 quarters.
  • Citadel Advisors's Kinnate Biopharma Inc. Common Stock position peaked at $52.3M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Kinnate Biopharma Inc. Common Stock as of Q2 2024.

Based on Citadel Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.